Cargando…
HSD97 Treatment Utilization and Key Characteristics of COVID-19 Patients Treated with Monoclonal Antibody Therapy in the Outpatient Setting
Autores principales: | Devine, F., Clary, A., Liu, J.H., Wu, Y.C., Park, J., Bhat, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256489/ http://dx.doi.org/10.1016/j.jval.2023.03.1404 |
Ejemplares similares
-
Delivering Monoclonal Antibody Infusions to Novel Outpatient Settings
por: Minnich, Amy, et al.
Publicado: (2022) -
LGI1-antibody associated epilepsy successfully treated in the outpatient setting
por: Uribe-San-Martín, R., et al.
Publicado: (2020) -
HSD97 Use Machine Learning (ML) Techniques to Identify the Likelihood of Hospitalization for High-Risk Patients Diagnosed with COVID 19
por: Mehta, RR, et al.
Publicado: (2022) -
HSD99 Telemedicine and the Utilization of Outpatient Mental Health Services By Patients with Incident Major Depressive Disorder during the COVID-19 Pandemic
por: Axeen, S., et al.
Publicado: (2023) -
HSD42 Trends in Non-COVID Healthcare Utilization during the Pandemic in Lebanon
por: Alameddine, R, et al.
Publicado: (2022)